By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics said after the close of the market Tuesday that it will conduct BRCA testing on patients enrolled in an Abbott Laboratories drug study.

Myriad will perform BRCA1 and BRCA2 mutation testing on patients in the Phase III, multi-center study of an Abbott drug for metastatic breast cancer. The Salt Lake City-based firm said that the agreement is similar to a previous agreement for a Phase II study of the same drug.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.

Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.

Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.

In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.